BIO
$268.83
Bio-Rad Laboratories
($1.05)
(.39%)
BIO
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $1.76
Revenue:  $610.65 Mil
Thursday
Jan 31
4:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 01, 2018

What do you expect when BIO reports earnings?
Beat
Meet
Miss

Where is BIO's stock price going from here?
Up
Flat
Down
Stock chart of BIO
Analysts
Summary of analysts' recommendations for BIO
Score
Grade
Pivots
Resistance
$282.57
$279.36
$274.09

$270.88

Support
$265.61
$262.40
$257.13
Tweet
Growth
Description
Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California.
Peers
IlluminaPerkinElmerAgilent TechnologiesCoherentTranslate BioHarvard Bioscience